GlaxoSmithKline to hold summit with major shareholders as board seeks to secure backing for boss Emma Walmsley and plans to split business
Under pressure: Boss Emma Walmsley GlaxoSmithKline will hold a summit with major shareholders next week as the board seeks to secure backing for chief executive Emma Walmsley and her plans to split the business. The one-hour crunch meeting on October 7 will be spearheaded by the pharma giant's chairman Jonathan Symonds and senior independent director Vindi Banga, who is also a senior partner at Clayton, Dubilier & Rice, the private equity firm bidding for Morrisons.
An activist investor pushing for a shake-up at GlaxoSmithKline has secured a meeting with the drugs giant's chairman – and the backing of corporate raider Elliott. Sources said Bluebell Capital Partners is due to meet Sir Jonathan Symonds within weeks. Bluebell wants GSK chief executive Emma Walmsley to reapply for her job ahead of the separation of the group's biopharma and consumer businesses next year.
Second GlaxoSmithKline activist targets boss Emma Walmsley demanding she reapply for her job GlaxoSmithKline boss Emma Walmsley is facing demands from a second activist investor that she reapply for her own job. Bluebell Capital Partners, a London asset manager, wants a ‘thorough and robust’ process to choose a leader after the pharmaceuticals and consumer businesses are separated.
Bluebell Capital takes stake in pharma giant and puts pressure on Emma Walmsley GSK’s chief executive, Emma Walmsley, has come under pressure from a second activist hedge fund, Bluebell Capital Partners, which has taken a stake in the drugmaker to push for change at the top, including demanding that she reapply for her job.
The shot is being made with South Korean group SK Bioscience It will be rolled out worldwide next year if the study is successful The trial will be a major boost for Walmsley, who is fending off an aggressive campaign against her leadership from activist investor Elliott Advisors GlaxoSmithkline has stepped up its battle against Covid as a vaccine it is co-developing entered final-stage clinical trials.
GlaxoSmithkline has stepped up its battle against Covid as a vaccine it is co-developing entered final-stage clinical trials. The shot, which is being made with South Korean group SK Bioscience, will be rolled out worldwide next year if the study is successful. The trial will be a major boost for chief executive Emma Walmsley, who is fending off an aggressive campaign against her leadership from activist investor Elliott Advisors.
DRUGMAKER GlaxoSmithKline today stepped up its role in the vaccine race as a Covid-19 shot developed with SK Bioscience entered final-stage clinical trials, paving the way for worldwide roll-out next year. The FTSE100 giant said the GBP510 jab created with the South Korean biopharma had triggered a strong antibody response in patients with no safety concerns in early phase studies.
Revealed: The drug chiefs topping the pay charts, with packages of more than £15m despite the pandemic
Pay was still high for firms that accepted taxpayer support during the pandemic Astrazeneca's Pascal Soriot was the UK's highest-paid FTSE 100 boss Emma Walmsley, boss of British drugs giant Glaxosmithkline, was the FTSE 100’s best-paid female chief executive last year Fat cat pay at blue-chip firms fell last year amid pandemic belt-tightening – but bosses still bagged millions.
Stand firm against activists, Emma! Pascal Soriot from rival AstraZeneca gives backing to besieged Glaxo boss
Emma Walmsley of Glaxosmithkline is facing an assault from activist investors Pascal Soriot's intervention in defence of a rival is largely based on his own experience and that of his board in repelling a bid from US pharma giant Pfizer He rejected the claim from Elliott Advisers that Walmsley was unsuited to heading GSK's pharma and vaccines arm because she isn't a scientist
GlaxoSmithKline has posted a jump in sales and profits for the past three months as the drugs giant said it was “encouraged” by the speed of Covid-19 vaccinations in the UK and other countries. The firm – which is spinning off its consumer healthcare arm – revealed that turnover increased by 6% to £8.1 billion for the second quarter of 2021 as it saw some coronavirus disruption fade.
GSK profits beat forecasts 07.14 EDT GSK has beaten forecasts with profits for the second quarter, after hospital visits picked up as Covid-19 restrictions were eased, boosting vaccine sales. This means its expected drop in 2021 profit will be smaller than thought. Sales rose to £8.1bn between April and June, up 15% at constant exchange rates which strip out currency fluctuations.
The head of the British pharmaceutical giant GSK, Emma Walmsley, will present the company's quarterly results on Wednesday as criticism mounts over ineffective management and delays in Covid-19 vaccine production. She is one of a small number of women to lead a large UK company and has become a fixture of global business circles after boosting GSK’s research efforts.
Business leaders are expected to raise problems caused by the ‘pingdemic’ at a meeting hosted by Boris Johnson on Thursday, Sky News understands. Boris Johnson will hold talks with some of Britain’s leading business figures this week amid continued frustration over changing private sector exemptions from coronavirus quarantine restrictions.
Pharma chief secured the City's backing for her demerger plan, but inside the company some remain far from convinced When Dame Emma Walmsley presented her vision for GlaxoSmithKline’s future at capital markets day last month, it was investors who were front and centre of her mind.
GlaxoSmithKline commits to £400m drug research site as boss battles to fend off US hedge fund Elliot
GlaxoSmithKline boss Emma Walmsley has made her boldest move yet in her battle to fend off a US hedge fund and hold on to her job. Less than a month after announcing plans to split in two, the UK drugs group has unveiled a project to build one of Europe's largest biotechnology campuses in Stevenage.